ArticleJournal of neural transmission (Vienna, Austria : 1996)2026
EEG power spectral and microstate analyses in the 22q11.2 deletion syndrome: from genetic risk to schizophrenia.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The 22q11.2 deletion syndrome (22q11.2DS) is a genetic disorder frequently associated with schizophrenia, whose study could shed light on the neurophysiological basis of psychotic risk and disease onset. We tested the hypothesis of a disrupted resting-state in electroencephalography (EEG), which we expected to be more perturbed in 22q11.2DS with schizophrenia relative to those without, and to controls. We retrospectively included 39 individuals (11 controls, 12 22q11.2DS, and 16 22q11.2DS with schizophrenia) with available routine EEG, who were compared for: (1) power spectral density (PSD) and the relative PSD alpha peak; (2) connectivity, based on the weighted phase lag index, and the relative global connectivity alpha peak; (3) microstates, described by their occurrence, temporal coverage, and mean duration. Microstates were built on controls and applied on the 22q11.2DS groups, which were compared with each other. We observed that 22q11.2DS with schizophrenia showed an increase in theta PSD (p = 2e⁻4), a decrease in average relative alpha power (p = 0.04) and global connectivity (p = 0.03), compared to healthy controls, while 22q11.2DS without schizophrenia had values between the controls and the subjects with 22q11.2DS and schizophrenia, with no significant differences with either groups. Microstate analysis found a significant increase in class C in patients with schizophrenia compared to those without (p = 0.045). These group-level neurophysiological anomalies may be present across the clinical trajectory, from genetic risk to chronic disease in 22q11DS, suggesting a potential relevance for a staging approach to early intervention in psychiatry.
Indexed as
Identifiers
41874714What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.